Anagen Technologies, Inc. is a small biotech company focused in the emerging field
of Pharmacogenetix. The Company has developed (Patent Filed; March
2001) a simple but powerful technology for SNP Scoring. The technology
can be implemented in several formats including Microfluidics,
Capillary Electrophoresis, PAGE and HPLC..
CEO: Saeed
Raees
Phone:(404) 223-5090
www.ana-gen.com
GeneCure, LLC is a
privately owned biotechnology company which is developing gene-based
technology to treat many human diseases (genetic and acquired). The
company’s business strategy is to enter corporate partnership
with pharmaceutical companies to commercialize gene-based therapeutics
developed based on its proprietary technology.
CEO: Frank
Tung
Phone:(404) 222-0611
www.genecure.com
Kinetic Biosystems, Inc. is a corporation formed in 1997 to commercialize
the science developed and patented by Dr. Heath Herman. The
CBR technology creates a fluidized bed of extremely dense concentrations
of microorganisms or mammalian cells up to ten thousand times
more concentrated than existing systems – and which enables
a continuous flow of liquid and nutrient to be processed through
this bed. The implications for many marketplaces are dramatic.
Broad patents covering this breakthrough in technology were
granted in the United States in 1997, 1998 and 2001, with foreign
equivalents and additional patents pending. As of 09/30/01,
KBI has invested $4.3 Million into developing this technology.
CEO: Anthony
Laughrey
Phone:(404) 607-7331
www.kbi-usa.com
KPS Technologies produces unique cyanine dyes that absorb
and fluoresce at near-infrared wavelengths. These molecules
are useful as detection units since virtually all organic materials
including biological tissues are penetrated by NIR radiation. Potential
applications are quite varied but those of interest are diagnostic
ones including protein labeling, immunoassays and DNA sequencing. The
major market for these compounds will be instrument manufacturers. Custom
made kits are available upon request.
Contact: Lucjan
Strekowski
Phone:(404) 651-0999
E-mail:lucjan@gsu.edu
Gabor Patonay
Phone:(404) 651-3856
E-mail:cheggp@panther.gsu.edu
Somatocor is
an emerging pharmaceutical company focused on the discovery,
development and commercialization of novel drugs for the treatment
of severe endocrine and metabolic disorders along with certain
types of cancer. Our unique molecules will be effective against
carcinoid tumors, acromegaly and diabetic retinopathy. We
have developed a series of proprietary drug candidates that
mimic the beneficial
effects of the naturally occurring hormone somatostatin. These
drugs were designed using our own proprietary HBM discovery
technologies. The company is backed by Alliance Technology
Ventures, one of the
largest venture capital firms in the Southeast.
Contact:Tony
Shuker
Phone:(404) 641-6186
E-mail:ashuker@somatocor.com
www.somatocor.com (under
construction)
Synar Technologies, Inc. is a chemistry/materials contract research and development
company. Their core technology is focused on designing and
developing molecules known as porphyrins. Leveraging advances
for producing low cost porphyrins in large scale, Synar hopes
to partner with industry and academia engaged in developing
materials that will be commercially viable in a variety of
applications.
CEO: Eric
Nickel
Phone: (404) 651-3855
E-mail:enickel@gsu.edu
Zygogen LLC is a privately held company founded in
1999 to leverage its proprietary transgenic Zebrafish technology,
Z-tag™, for both the conversion of genomic information into
medicinal leads and the screening of drug candidates. Zygogen
offers flexible problem solving for its biotechnology and pharmaceutical
partners. Alliances will be designed to facilitate a close
working relationship with partners, including assay development
and technology transfer between partners.
CEO: Nina
Sawczuk
Phone: (404) 523-7309
www.zygogen.com
